For a beneficiary to qualify, their provider must submit a prior authorization request that attests the beneficiary is being prescribed the drug to reduce excess body weight and ongoing maintenance of weight reduction and that they fall into one of three categories related to BMI and other clinical diagnostic criteria (Figure 3)
Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28,29,30]
Stay away from pushy providers and those who fudge necessary consultations
Do not address the biological root causes of hunger and cravings
The scoping review by Legesse et al
This becomes particularly relevant in the context of GLP-1 receptor agonist therapy, where the substantial weight loss these medications produce is not exclusively fat loss